On Target In Fiscal Q4
There are always plenty of moving parts within Pall's results, as the company sells into so many different end markets, but the end result performance was pretty much on target.
Revenue fell almost 1% as reported to close the fiscal year, but revenue in local currency terms rose half a point. Life sciences was up 6% for the quarter, as strength in biopharma offset weaker conditions in the Chinese and European food and beverage sector. Customer utilization levels in industrial markets remain a real issue, though, and the company saw a 5% decline (local currency) in industrial sales, with particular weakness in microelectronics and municipal water.
Hot Industrial Disributor Companies To Own In Right Now: Novartis AG (NOVN)
Novartis AG provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. It has five segments: Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals; vaccines and diagnostics, which include human vaccines and blood-testing diagnostics, and consumer health, which include over-the-counter medicines (OTC) and Animal Health. In February 2014, it acquired CoStim Pharmaceuticals, Inc. Advisors' Opinion:- [By Sofia Horta e Costa]
Novartis AG (NOVN) slipped 1.3 percent to 67.20 Swiss francs after JPMorgan Chase cut its recommendation on the drugmaker to neutral from overweight, a rating similar to buy. The stock has rallied 17 percent so far this year, compared with a 15 percent increase for the Swiss Market Index.
- [By Corinne Gretler]
Novartis AG (NOVN) climbed 2 percent to 69.25 Swiss francs after raising its full-year forecasts. Sales will increase at a low-to mid-single-digit percentage rate in constant currencies, and core operating income will match or exceed the previous year, Europe�� biggest drugmaker said. In July, the company forecast a low-single-digit percentage decline in earnings in 2013, with sales rising at a similar rate.
10 Best Life Sciences Stocks To Buy For 2014: Archer-Daniels-Midland Company(ADM)
Archer Daniels Midland Company procures, transports, stores, processes, and merchandises agricultural commodities and products in the United States and internationally. It operates in three segments: Oilseeds Processing, Corn Processing, and Agricultural Services. The Oilseeds Processing segment engages in originating, merchandising, crushing, and processing oilseeds, such as soybeans, cottonseed, sunflower seeds, canola, rapeseed, peanuts, flaxseed, and palm into vegetable oils and protein meals. This segment also produces edible soy protein products, including soy flour, soy grits, soy protein concentrates, soy isoflavones, and soy isolates that are used in processed meats, baked foods, nutritional products, snacks, and dairy and meat analogs. The Corn Processing segment involves in corn wet milling and dry milling activities; and produces alcohol, amino acids, and other specialty food and animal feed ingredients, as well as ethyl alcohol. This segment also produces citr ic and lactic acids, lactates, sorbitol, xanthan gum, and glycols that are used in various food and industrial products, as well as astaxanthin, a product used in aquaculture to enhance flesh coloration. The Agricultural Services segment buys, stores, cleans, and transports agricultural commodities, such as oilseeds, corn, wheat, milo, oats, rice, and barley, as well as resells these commodities as food and feed ingredients for the agricultural processing industry. This segment also processes and distributes edible beans, formula feeds, and animal health and nutrition products. In addition, the company engages in milling wheat, corn, and milo into flour, as well as produces bakery products and mixes, wheat starch, gluten, and cocoa products that are sold to the baking industry; and involves in financial activities related to private equity fund investments, and futures commission merchant activities. Archer Daniels Midland Company was founded in 1898 and is based in Decatur, Illinois.
Advisors' Opinion:- [By Sure Dividend]
No matter how much information we have, people will always need to eat. One way to look at if an industry has managed to grow over decades is to see how many Dividend Aristocrats the industry claims. Dividend Aristocrats are businesses that have increased their dividend payments for 25 or more consecutive years, and meet certain size and liquidity requirements. These are businesses that have withstood all of the changes of the last 25 or more years, and managed to grow consistently and profitably. There are 54 Dividend Aristocrats. The list below shows the Dividend Aristocrats whose primary business relates to food and/or beverages:
McDonald�� (MCD) Coca-Cola (KO) PepsiCo (PEP) McCormick & Co. (MKC) Archer-Daniels-Midland (ADM) Hormel Foods (HRL) Brown-Forman (BF.B) Sysco (SYY)Of the 54 Dividend Aristocrats, eight (~15%) make their money from food and/or beverages. Interestingly, six of the seven (ADM and SYY are the exception) make their money from branded consumer food and beverages. If you are looking for slow-changing businesses that grow year after year, branded food companies are a good place to search.
- [By Paul Ausick]
Ethanol producers and farmers are the losers and the RFA is steaming mad. The group claims that the ��PA is proposing to place the nation�� renewable energy policy in the hands of the oil companies.��Producers like Archer Daniels Midland Co. (NYSE: ADM), Pacific Ethanol Inc. (NASDAQ: PEIX), and The Andersons Inc. (NASDAQ: ANDE) don�� have an oil refining business to offset the proposed cuts to ethanol volumes.
10 Best Life Sciences Stocks To Buy For 2014: POWERSHARES DYNAMIC BLDG & CONSTR PORT (PKB)
PowerShares Dynamic Building & Construction Portfolio (the Fund) seeks investment results that correspond generally to the price and yield of an equity index called the Dynamic Building & Construction Intellidex Index (the Building & Construction Intellidex). The Building & Construction Intellidex consists of stocks of 30 United States building and construction companies. These are companies that are primarily engaged in providing construction and related engineering services for building and remodeling residential properties, commercial or industrial buildings, or working on large-scale infrastructure projects, such as highways, tunnels, bridges, dams, power lines and airports. These companies may also include manufacturers of building materials for home improvement and general construction projects, and specialized machinery used for building and construction; companies that provide installation/maintenance/repair work, and land developers. Stocks are selected principally on the basis of their capital appreciation potential as identified by the AMEX (the Intellidex Provider) pursuant to an Intellidex methodology. The Fund�� investment advisor is PowerShares Capital Management LLC.
The Fund, using an indexing investment approach, attempts to replicate the performance of the Building & Construction Intellidex. The Fund generally will invest in all of the stocks comprising the Building & Construction Intellidex in proportion to their weightings in the Building & Construction Intellidex. The Fund will normally invest at least 80% of its total assets in common stocks of building and construction companies. It will normally invest at least 90% of its total assets in common stocks that comprise the Building & Construction Intellidex.
Advisors' Opinion:- [By John Udovich]
Small cap building materials stock NCI Building Systems Inc (NYSE: NCS) fell yesterday after announcing a share offering plus its investors have (so-far) missed out on any ��ecovery��in construction���meaning it might be time to take a closer look at the stock along with potential performance benchmarks like the PowerShares Dynamic Building & Construction ETF (NYSEARCA: PKB) and the First Trust ISE Global Engineering and Construction Index Fund ETF (NYSEARCA: FLM)���both of which have had decent returns in recent years.
10 Best Life Sciences Stocks To Buy For 2014: Empresas Ica Soc Contrladora (ICA)
Empresas ICA, S.A.B. de C.V., through its subsidiaries, engages in the construction and related activities in Mexico. The company?s Civil Construction segment focuses on infrastructure projects that include the construction of roads, highways, mass transit systems, bridges, dams, hydroelectric plants, tunnels, canals, and airports; and on the construction, development, and remodeling of multi-storied urban buildings, such as office buildings, hotels, multiple-dwelling housing developments, and shopping centers. This segment also engages in demolition, clearing, excavation, de-watering, drainage, embankment fill, structural concrete construction, concrete and asphalt paving, and tunneling activities. Its Industrial Construction segment focuses on the engineering, procurement, construction, design, and commissioning of manufacturing facilities comprising power plants, chemical plants, petrochemical plants, fertilizer plants, pharmaceutical plants, steel mills, paper mills, d rilling platforms, and automobile and cement factories. Empresas ICA?s Rodio Kronsa segment engages in sub-soil construction involving the construction of tunnels, underpasses, and retaining walls. The company?s Housing Development segment engages in the development, trading, ownership, sale, assistance, operation, and administration activities. Its Infrastructure segment involves in the operation and maintenance of concessioned airports, highways, bridges and tunnels, water supply systems, and waste treatment systems. The company also provides a range of services that include feasibility studies, conceptual design, engineering, procurement, project and construction management, construction, maintenance, technical site evaluation, and other consulting services. It serves public and private sector clients. Empresas ICA, S.A.B. de C.V. was founded in 1947 and is based in Mexico.
Advisors' Opinion:- [By Michael Lewis]
It's been said plenty of times that our neighbor to the south is home to a burgeoning, debt-light economy that offers emerging-market growth with an element of domestic risk and valuation. China is very much "last season" when it comes to manufacturing, and Mexico offers a fantastic answer, with geographical superiority and an eager work force. One company based in Mexico, Empresas ICA (NYSE: ICA ) , is a heavy-construction firm with a market cap of $1 billion that was as recently as April worth nearly $2 billion. The causes for the haircut includes a collapsed deal and lousy first-quarter earnings. But with a strong outlook for Mexican infrastructure spending, and an apparent case of market negligence, Empresas ICA might be an undervalued pick with substantial upside potential.
10 Best Life Sciences Stocks To Buy For 2014: Companhia de Bebidas das Americas - AmBev(ABV)
Companhia de Bebidas das Americas?Ambev engages in the production, distribution, and sale of beer, draft beer, carbonated soft drinks, malt, and other non-alcoholic and non-carbonated products in the Americas. It also sells bottled water, isotonics, and ready-to-drink teas. The company provides its products under the brand names of Skol, Brahma, Antarctica, Guarana Antarctica, Gatorade, Brahva, Brahva Beats, Extra, Brahma Light, Brahma Ice, Quilmes, Stella Artois, Red Rock, Pepsi-Cola, Seven UP, Zenda, Concordia, Triple Kola, Quilmes Cristal, Brahma, Andes, Pacena, Taquina, Huari, Becker, Baltica, Pilsen, Patricia, Labatt Blue, Alexander Keith?s, and Kokanee. It has a licensing agreement with Anheuser-Busch, Inc. to produce, bottle, distribute, and sell Budweiser products in Canada and Paraguay. Companhia de Bebidas das Americas?Ambev distributes its products through direct distribution system and third-party distributors. The company was founded in 1888 and is headquarter ed in Sao Paulo, Brazil. Companhia de Bebidas das Americas?Ambev is a subsidiary of Interbrew International B.V.
Advisors' Opinion:- [By Dividend]
Companhia de Bebidas Das Americas (ABV) has a market capitalization of $118.32 billion. The company employs 51,299 people, generates revenue of $14.120 billion and has a net income of $4.662 billion. Companhia de Bebidas Das Americas�� earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $6.829 billion. The EBITDA margin is 48.36 percent (the operating margin is 43.00 percent and the net profit margin 33.02 percent).
- [By Hilary Kramer]
Companhia de Bebidas das Americas (ABV): Better known as Ambev, it is one of the largest brewers in the world and the largest in Latin America (in terms of sales volume). It makes a variety of beverages, including beer and soft drinks, and is also one of the biggest independent PepsiCo bottlers in the world. The company has done a good job lately of emphasizing premium beers, which carry a higher margin, to offset recent lower sales volumes. ABV yields a solid 4.6%.
- [By Robert Martin]
South Africa, China, Mexico and Brazil collectively make up 68% of ECON�� holdings. The top three holdings are Naspers LTD (NPSNY) at 10%, AmBev (ABV) at 8% and FEMSA (FMX) at 5.6%.
10 Best Life Sciences Stocks To Buy For 2014: CryoLife Inc (CRY)
CryoLife, Inc. (CryoLife,), incorporated in January 19,1984, is a biological medical device company. The Company preserves and distributes human tissues for transplantation and develops, manufactures, and commercializes medical devices for cardiac and vascular applications. The cardiac and vascular human tissues distributed by CryoLife include the CryoValve SG pulmonary heart valve (CryoValve SGPV) and the CryoPatch SG pulmonary cardiac patch tissue (CryoPatch SG), both processed using CryoLife�� SynerGraft technology. The Company operates in two segments: preservation services and medical devices segment. The preservation services segment includes services revenues from the preservation of cardiac and vascular tissues during the year ended December 31, 2011. The medical devices segment includes revenues from product sales of BioGlue, BioFoam, PerClot, HemoStase and revascularization technologies, as well as sales of other medical devices. CryoLife�� surgical sealants and hemostats include BioGlue Surgical Adhesive (BioGlue), BioFoam Surgical Matrix (BioFoam) and PerClot, an absorbable powdered hemostat. In May 2011, it acquired Cardiogenesis Corporation. In May 2012, the Company acquired Hemosphere, Inc. Hemosphere develops and markets the HeRO (Hemodialysis Reliable Outflow) Graft, a graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with limited access options and central venous obstruction. In February 2014, CryoLife Inc announced the establishment of CryoLife Asia Pacific Pte. Ltd.
CryoLife distributes preserved human cardiac and vascular tissues to implanting institutions throughout the United States (U.S), Canada and Europe. CryoLife processes and preserves cardiac and vascular tissues using processing and freezing techniques, or cryopreservation. The Company�� preservation process involves the recovery of tissue from deceased human donors by tissue banks and organ procurement organizations (OTPOs), the delivery, of such tissue to the Company, the s! creening, dissection, disinfection, processing, and preservation of the tissue by the Company, and the storage and shipment of the preserved tissue.
The human heart valves and cardiac patch tissues preserved by the Company are used in cardiac reconstruction and heart valve replacement surgeries. The Company preserves human aortic and pulmonary heart valves for implantation by cardiac surgeons. In addition, the Company preserves human cardiac patches for surgeons. The Company preserves human cardiac patches in three primarily anatomic configurations: pulmonary hemi-artery, pulmonary trunk and pulmonary branch. As of December 31, 2011, CryoLife shipped approximately 77,600 heart valves and cardiac patch tissues, including approximately 3,000 shipments during 2011.
The human vascular tissues preserved by the Company, including the CryoVein and CryoArtery, are used to treat a variety of vascular reconstructions, such as peripheral bypass, hemodialysis access and aortic infections. The Company preserves small diameter human saphenous vein conduits (3 millimeter to 6 millimeter) for use in peripheral vascular reconstructions. The Company also preserves femoral veins and arteries and aortoiliac arteries for bypass, hemodialysis access, or reconstruction within infected surgical areas. As of December 31, 2011, the Company shipped approximately 66,100 human vascular tissues, including approximately 4,500 shipments during 2011.
CryoLife�� product BioGlue, designed for cardiac, vascular, pulmonary, and general surgical applications, is a polymer based on bovine blood protein and an agent for cross-linking proteins. CryoLife distributes BioGlue throughout the United States and approximately 75 other countries. CryoLife distributes BioGlue for repair of soft tissues under conformite Europeene Mark Product Certification (CE Mark). CryoLife distributes BioGlue in Japan for use in the repair of aortic dissections.
CryoLife�� product, BioFoam, is a protein hydr! ogel biom! aterial with an expansion agent, which generates a mixed-cell foam. The foam creates a mechanical barrier to decrease blood flow and develops pores for the blood to enter, leading to cellular aggregation and enhanced hemostasis. CryoLife distributes BioFoam under CE Mark certification.
CryoLife�� product, PerClot, is an absorbable, powdered hemostatic agent used in surgery. PerClot particles have a molecular structure that absorbs water from blood, creating a high concentration of platelets, red blood cells, and coagulation proteins at the bleeding site, which accelerates the physiologic clotting cascade. PerClot is readily dissolved by saline irrigation and is totally absorbed within several days. PerClot is available in one gram, three gram and five gram sizes with a 100 millimeter or 200 millimeter applicator tip. PerClot Laparoscopic is available in one gram and three gram sizes with a 380 millimeter applicator tip.
The Company competes with St. Jude Medical, Inc., Medtronic, Inc., Edwards Life Sciences, Inc., Neovasc, Inc., LifeNet Health, Inc. W.L. Gore & Associates��Propaten, C.R. Bard, Inc., Hancock Jaffe Laboratories, Inc., Maquet, Inc., CorMatrix Cardiovascular, Inc., Baxter International, Inc., Johnson & Johnson Company, Covidien Ltd, NeoMend, Inc., Pfizer, Inc., Orthovita, Inc., King Pharmaceuticals, Inc., Ethicon, Inc., ZymoGenetics, Inc. and Nycomed.
Advisors' Opinion:- [By Eric Volkman]
CryoLife (NYSE: CRY ) is putting some zip into its shares with a dividend boost. The company has declared a fresh quarterly distribution of $0.0275 per share, to be paid on June 21 to shareholders of record as of June 14. This marks the company's first-ever dividend increase -- the new amount is 10% higher than its three prior (and only) payouts, each of which totaled $0.025.
10 Best Life Sciences Stocks To Buy For 2014: Theravance Inc.(THRX)
Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines for various therapeutic areas, including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. The company?s key development programs with GlaxoSmithKline (GSK) include the RELOVAIR, a Phase 3 clinical trial program for the treatment of patients with chronic obstructive pulmonary disease (COPD) and/or asthma; the LAMA/LABA program, a Phase 3 COPD program; and the Bifunctional Muscarinic Antagonist-beta2 Agonist (MABA) program, a Phase 2b program for the treatment of COPD, as well as Peripherally Selective Mu-Opioid Receptor Antagonist (P Advisors' Opinion:
- [By Sean Williams]
The buzz in the health-care sector this week has nothing to do with earnings reports and everything to do with an expected PDUFA decision by the FDA on GlaxoSmithKline (NYSE: GSK ) and Theravance's (NASDAQ: THRX ) chronic obstructive pulmonary disease, or COPD, inhaled drug, Breo Ellipta.
- [By Sean Williams]
Perhaps the most exciting new treatment to hit the market in years was recently approved by the FDA. Developed by GlaxoSmithKline (NYSE: GSK ) and Theravance (NASDAQ: THRX ) , Breo Ellipta is a dry powder drug delivered by inhaler and meant to provide long-term relief of air-flow obstruction and reduce COPD exacerbations. The two companies are collaborating on a handful of potentially revolutionary new COPD treatments that combine Theravance's long-acting beta-2 agonists with Glaxo's long-acting muscarinic antagonists. Its next treatment, Breo Anoro, is currently under review by the FDA.
- [By Sean Williams]
Things are about to getting very exciting for existing shareholders of biopharmaceutical company Theravance (NASDAQ: THRX ) , with the company announcing its first-quarter results after the closing bell and setting a record date of May 15 for its split into two separate trading entities.
No comments:
Post a Comment